Results 61 to 70 of about 13,054 (213)

Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma

Pharmaceuticals, 2023
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Development of the chemoresistance in the PDAC is one of the key contributors to the poor survival outcomes and the major reason for urgent development of ...
Nemanja Djokovic, Ana Djuric, Dusan Ruzic, Tatjana Srdic-Rajic, Katarina Nikolic   +4 more
doaj   +1 more source

CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages

Journal of Experimental & Clinical Cancer Research
Background Targeting oncogenic histone modification by histone deacetylase inhibitors (HDACis) demonstrates promising prospects in clinical cancer treatment, whereas a notable proportion of patients cannot benefit from HDACi therapy.
Xutao Xu, Qianqian Wang, Ke Guo, Junjie Xu, Yunkun Lu, Huijuan Chen, Weilin Hu, Yilin Fu, Lu Sun, Ying He, Zhehang Chen, Wenhao Xia, Mengtian Pan, Beibei Lin, Wenjuan Yang, Qingqing Wang, Zhenzhen Wen, Qian Cao, Peng Xiao   +18 more
doaj   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Cdk4 mRNA and protein expression in BV2 microglia treated with HDACi.

, 2014
A. qRT-PCR analysis shows that Cdk4 mRNA expression is significantly upregulated in LPS-treated BV2 microglia and however, downregulated when cells are treated with HDACi. B–C.
Jia Lu (181094), Yali Li (198373), Eng-Ang Ling (480548), Nimmi Baby (524594), S. Thameem Dheen (420646)   +4 more
core   +1 more source

Sensitization of hepatocellular carcinoma cells to HDACi is regulated through hsa-miR-342-5p/CFL1

Cancer Cell International
Background Increased prevalence of hepatocellular carcinoma (HCC) remains a global health challenge. HCC chemoresistance is a clinical obstacle for its management.
Parvathi Nakka, Chikondi Jassi, Ming-Cheng Chen, Yi-Sheng Liu, Jer-Yuh Liu, Chung-Min Yeh, Chi-Cheng Li, Yu-Chun Chang, Wei-Wen Kuo, Chih-Yang Huang   +9 more
doaj   +1 more source

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma

Frontiers in Cell and Developmental Biology, 2020
Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure. An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in
Monica Phimmachanh, Jeremy Z. R. Han, Yolande E. I. O’Donnell, Sharissa L. Latham, Sharissa L. Latham, David R. Croucher, David R. Croucher   +6 more
doaj   +1 more source

Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching

Journal of Cellular Physiology, Volume 241, Issue 6, June 2026.
This graphical abstract summarizes the major immune‐evasion mechanisms that limit immunotherapy efficacy in ovarian cancer peritoneal metastasis. Peritoneal dissemination is shaped by impaired antigen visibility, coordinated immune‐evasion modules within ascites and multicellular spheroids, checkpoint‐driven T‐cell exhaustion, suppressive tumor ...
Xiaodong Wang, Junjie Wang, Di Xiong, Songli Cui, Qianqian Wang, Yiping Huang, Gouping Ding, Yixuan Tang, Yeqian Feng   +8 more
wiley   +1 more source

Research Progress of Histone Deacetylase Inhibitor Combined with 
Immune Checkpoint Inhibitor in the Treatment of Tumor

Chinese Journal of Lung Cancer, 2021
Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex,
Chen FANG, Yong WANG, Yong LI
doaj   +1 more source

NO productionin BV2 microglia transfected with Runx1t1 siRNA or treated with HDACi.

, 2014
A–B. Nitric oxide (NO) assay analysis indicates that nitrite level is significantly increased in LPS-treated BV2 microglial cells and is brought down to near base level either by Runx1t1 siRNA knockdown(A) or by HDACi treatment (B).
Jia Lu (181094), Yali Li (198373), Eng-Ang Ling (480548), Nimmi Baby (524594), S. Thameem Dheen (420646)   +4 more
core   +1 more source

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)

, 2020
Histone deacetylase inhibitors (HDACi) are already approved for the therapy of leukemias. Since they are also emerging candidate compounds for the treatment of non-malignant diseases, HDACi with a wide therapeutic window and low hazard potential are ...
Lena Schumacher, Thomas Kurz, Annabelle Friedrich, Matthias U. Kassack, Gerhard Fritz, Wynand P. Roos, Finn K. Hansen, Marc Pflieger, Jana v. Stuijvenberg, Wolfgang A. Schulz, Ann-Sophie Assmann   +10 more
core   +1 more source